Golden Seeds Cognition Therapeutics LLC
Known title: 10% OwnerCIK: 0001884796
Associated companies
Transaction History
| CGTX | ▼ Sell | Other | 2,489,682 | $0 | 9/27/2022 | View on chart |
| CGTX | ▼ Sell | Other | 273,321 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 167,721 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 1,237,959 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 486,742 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 12,276 | $393 | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Open Market | 33 | $397 | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 311,706 | — | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.